Ubiquitin D as a potential therapeutic target for NASH, HCC and chronic kidney diseases

泛素 D 作为 NASH、HCC 和慢性肾脏疾病的潜在治疗靶点

基本信息

  • 批准号:
    10666292
  • 负责人:
  • 金额:
    $ 50万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-01 至 2028-05-31
  • 项目状态:
    未结题

项目摘要

Abstract: Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), is one of the major causes of cirrhosis and hepatocellular carcinoma (HCC). There is currently no approved treatment for NASH and patients with advanced fibrosis are at highest risk of mortality due to cardiovascular diseases (CVD). Furthermore, presence of NAFLD increases the risk of chronic kidney disease (CKD) by about 80%. It is not known how NASH and CKD influence each other, but together they can influence CVD and patient mortality. Therefore, a therapeutic target that can improve NASH and its associated co-morbidities such as CKD and CVD will be of great benefit in clinics. We found that Ubiquitin D (UBD) is highly upregulated in NASH livers (primarily in the hepatocytes), HCC tumors and kidneys of CKD mice. Interestingly, UBD was recently found to be one of the six progression-related genes that play a vital role in the progression of NAFLD and positively correlates with steatosis, ballooning, inflammation, fibrosis and NAS score. Similarly, multiple reports link renal UBD to proteinuria and kidney disease. UBD is known to participate in alternative ubiquitination pathway and interact with key cellular proteins such as p53, p62 and MAD2 but the precise mechanism of its role in NASH/HCC and CKD remains unclear. Absence of UBD (in Ubd-/- mice) improved overall metabolic health and extended the mouse lifespan. Despite all the compelling evidences, UBD has not been tested as a therapeutic target for NASH and CKD. Here, we propose to suppress UBD using anti-sense oligos (ASOs) as a therapeutic approach to treat NASH and CKD. We have already developed a “GalNAc” conjugated ASO that is potent in suppressing UBD gene expression in the hepatocytes. Our preliminary data indicates that anti-UBD GalNAc-ASO significantly improved NASH and fibrosis. According to our knowledge, UBD pathway has not been investigated for its therapeutic potential before and also is not a current focus of any industry or academia. Therefore, UBD is a novel target and anti-UBD ASOs provide novel therapeutic leads with a potential to improve both NASH and CKD. We will take advantage of a unique pre-clinical mouse model of diet-induced NASH that also develop CKD and CVD with mortality at later stages (established in our lab). We will address whether anti-UBD ASOs could improve all three disease outcome along with survival benefit. We will supplement this model with additional preclinical models of NASH, HCC and CKD. The following 2 Specific Aims will be addressed in this proposal: Aim 1 will Identify whether UBD suppression prevents NASH and its progression to Cirrhosis and HCC. Additionally, we will translate our findings to human using human primary cell derived 3-D spheroid cell cultures. Aim 2 will investigate the effect of UBD suppression on CKD, CVD and survival benefit either in the context of NASH and/or CKD. Successful completion of the proposed aims will establish UBD as a novel therapeutic target for NASH and CKD.
抽象的: 非酒精性脂肪性肝炎(NASH)是非酒精性脂肪性肝病(NAFLD)的一种高级形式,是一种 肝硬化和肝细胞癌(HCC)的主要原因。目前尚无批准的治疗方法 NASH 和晚期纤维化患者因心血管疾病 (CVD) 死亡的风险最高。 此外,NAFLD 的存在会使慢性肾病 (CKD) 的风险增加约 80%。它不是 我们知道 NASH 和 CKD 如何相互影响,但它们共同影响 CVD 和患者死亡率。 因此,可以改善 NASH 及其相关并发症(如 CKD 和 CVD)的治疗靶点 将在临床上大有裨益。 我们发现泛素 D (UBD) 在 NASH 肝脏(主要在肝细胞)、HCC 中高度上调 CKD 小鼠的肿瘤和肾脏。有趣的是,最近发现 UBD 是六种与进展相关的疾病之一 这些基因在 NAFLD 的进展中发挥着至关重要的作用,并与脂肪变性、气球样变、 炎症、纤维化和 NAS 评分。同样,多项报告将肾 UBD 与蛋白尿和肾脏疾病联系起来。 已知 UBD 参与替代泛素化途径并与关键细胞蛋白相互作用,例如 p53、p62 和 MAD2,但其在 NASH/HCC 和 CKD 中作用的确切机制仍不清楚。不存在 UBD(在 Ubd-/- 小鼠中)改善了整体代谢健康并延长了小鼠的寿命。尽管所有的 令人信服的证据表明,UBD 尚未作为 NASH 和 CKD 的治疗靶点进行过测试。在此,我们建议 使用反义寡核苷酸 (ASO) 抑制 UBD 作为治疗 NASH 和 CKD 的方法。我们有 已经开发出一种“GalNAc”缀合 ASO,可有效抑制 UBD 基因表达 肝细胞。我们的初步数据表明,抗 UBD GalNAc-ASO 显着改善了 NASH 和 纤维化。据我们所知,UBD 通路之前尚未对其治疗潜力进行过研究 并且也不是任何行业或学术界当前关注的焦点。因此,UBD 是一个新的靶点和抗 UBD ASO 提供新的治疗线索,有可能改善 NASH 和 CKD。 我们将利用饮食诱导 NASH 的独特临床前小鼠模型,该模型也能开发 CKD 和 CVD 晚期死亡(在我们实验室建立)。我们将讨论是否存在反 UBD ASO 可以改善所有三种疾病的结果以及生存获益。我们将补充这个模型 NASH、HCC 和 CKD 的其他临床前模型。本计划将解决以下 2 个具体目标 提案:目标 1 将确定 UBD 抑制是否可以预防 NASH 及其进展为肝硬化和 肝癌。此外,我们将使用人类原代细胞衍生的 3-D 球状细胞将我们的发现转化为人类 文化。目标 2 将研究 UBD 抑制对 CKD、CVD 和生存获益的影响 NASH 和/或 CKD 的背景。成功完成拟议目标将使 UBD 成为一个新颖的 NASH 和 CKD 的治疗靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Debanjan Dhar其他文献

Debanjan Dhar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Debanjan Dhar', 18)}}的其他基金

Dissecting the Intracellular and Extracellular Role of TREM2 in the Pathogenesis of Non-Alcoholic Steatohepatitis.
剖析 TREM2 在非酒精性脂肪性肝炎发病机制中的细胞内和细胞外作用。
  • 批准号:
    10720352
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:

相似海外基金

Conference: Rethinking how language background is described in academia and beyond
会议:重新思考学术界及其他领域如何描述语言背景
  • 批准号:
    2335912
  • 财政年份:
    2024
  • 资助金额:
    $ 50万
  • 项目类别:
    Standard Grant
ADVANCE Catalyst: Virtual Observatory of Culture for Equity in Academia at the University of Puerto Rico Rio Piedras (VoCEA)
ADVANCE Catalyst:波多黎各 Rio Piedras 大学学术界平等文化虚拟观察站 (VoCEA)
  • 批准号:
    2214418
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
    Standard Grant
Comprehensive development strategy of modality-specific "intellectual property" and "cultivation" with an eye on "pharmaceutical affairs" in academia drug discovery
学术界新药研发着眼“药事”的模式“知识产权”与“培育”综合发展策略
  • 批准号:
    23K02551
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accelerating Research Advancement for Investigators Underrepresented in Academia
加速学术界代表性不足的研究人员的研究进展
  • 批准号:
    10746315
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
Planning: HBCU-UP: Strengthening Data Science Research Capacity and Education Programs through Academia-Industry Partnership
规划:HBCU-UP:通过学术界与工业界合作加强数据科学研究能力和教育计划
  • 批准号:
    2332161
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
    Standard Grant
From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer
从学术界到商界:针对 HPV 相关癌症的新型疗法的开发
  • 批准号:
    10813323
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
Academics4Rail: Building a community of railway scientific researchers and academia for ERJU and enabling a network of PhDs (academia teaming with industry)
Academys4Rail:为ERJU建立铁路科研人员和学术界社区并建立博士网络(学术界与工业界合作)
  • 批准号:
    10087488
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
    EU-Funded
Academics4Rail: Building a Community of Railway Scientific Researchers and Academia for ERJU and Enabling a Network of PhDs (Academia Teaming with Industry)
Academys4Rail:为二院建立铁路科研人员和学术界社区并启用博士网络(学术界与工业界合作)
  • 批准号:
    10102850
  • 财政年份:
    2023
  • 资助金额:
    $ 50万
  • 项目类别:
    EU-Funded
Exploring the overall picture of industry-academia-government collaboration: A spectrum of knowledge transfer through formal and informal channels
探索产学官合作的整体图景:通过正式和非正式渠道进行的一系列知识转移
  • 批准号:
    22K01692
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Fostering Ethical Neurotechnology Academia-Industry Partnerships: A Stakeholder Engagement and Toolkit Development Project
促进道德神经技术学术界与工业界的伙伴关系:利益相关者参与和工具包开发项目
  • 批准号:
    10655632
  • 财政年份:
    2022
  • 资助金额:
    $ 50万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了